Stock listing
A3CPAM Stock Price, News, Filings & Events — Sagimet Biosciences Inc. - Series A
Selected listing: A3CPAM · LS · EUR · DE
This page tracks Sagimet Biosciences Inc. - Series A's A3CPAM:LS listing on LS in EUR for DE, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following A3CPAM:LS. A3CPAM:LS is the stock-level entry point for investors researching Sagimet Biosciences Inc. - Series A, while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary.
- Ticker
- A3CPAM:LS
- Asset type
- Stock
- Market cap
- $631.3M
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- Exchange
- LS
- Currency
- EUR
Sagimet Biosciences Inc. - Series A A3CPAM:LS stock context
This page tracks Sagimet Biosciences Inc. - Series A's A3CPAM:LS listing on LS in EUR for DE, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following A3CPAM:LS. A3CPAM:LS is the stock-level entry point for investors researching Sagimet Biosciences Inc. - Series A, while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary.
Latest news from Sagimet Biosciences Inc. - Series A
Sagimet Biosciences Advances AURORA U.S. Phase 3 Trial of Denifanstat in Acne Toward Patient Enrollment in Q4 2026
August 25, 2026
Sagimet Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
August 17, 2026
Sagimet Biosciences Receives FDA “Study May Proceed” Letter and IND Clearance for Phase 3 Trial in Acne in Adolescent and Adult Patients
August 13, 2026
Sagimet Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
August 11, 2026
Sagimet Biosciences Joins the Russell 2000® and Russell 3000® Indexes
June 29, 2026
Research Sagimet Biosciences Inc. - Series A
Sagimet Biosciences Inc. - Series A investor report
Review AI stock analysis and investor report context for A3CPAM:LS.
Sagimet Biosciences Inc. - Series A company profile
View the public company page for Sagimet Biosciences Inc. - Series A on 6ix.
Sagimet Biosciences Inc. - Series A news
Read company news and market updates connected to Sagimet Biosciences Inc. - Series A.
Sagimet Biosciences Inc. - Series A investor events
Find investor webinars, events, and replay context for Sagimet Biosciences Inc. - Series A.
Alternate listings
SGMT:NASDAQ
US · USD
Alternate listing for Sagimet Biosciences Inc. - Series A; the primary context on this page is A3CPAM:LS.
0O2:GETTEX
DE · EUR
Alternate listing for Sagimet Biosciences Inc. - Series A; the primary context on this page is A3CPAM:LS.
SGMT:BOATS
US · USD
Alternate listing for Sagimet Biosciences Inc. - Series A; the primary context on this page is A3CPAM:LS.
A3CPAM:LSX
DE · EUR
Alternate listing for Sagimet Biosciences Inc. - Series A; the primary context on this page is A3CPAM:LS.
0O2:MUN
DE · EUR
Alternate listing for Sagimet Biosciences Inc. - Series A; the primary context on this page is A3CPAM:LS.
0O2:DUS
DE · EUR
Alternate listing for Sagimet Biosciences Inc. - Series A; the primary context on this page is A3CPAM:LS.
0O2:TRADEGATE
DE · EUR
Alternate listing for Sagimet Biosciences Inc. - Series A; the primary context on this page is A3CPAM:LS.
0O2:FWB
DE · EUR
Alternate listing for Sagimet Biosciences Inc. - Series A; the primary context on this page is A3CPAM:LS.
0O2:SWB
DE · EUR
Alternate listing for Sagimet Biosciences Inc. - Series A; the primary context on this page is A3CPAM:LS.